Schering-Plough’s Claritin
Executive Summary
Company is seeking 731 days of patent-term extension from the U.S. Patent and Trademark Office for the prescription antihistamine, approved April 12, FDA states in Aug. 31 Federal Register notice. The agency has determined that the regulatory review period for Claritin (loratadine) is 3,751 days. Of that time, 1,395 days occurred during the drug's testing phase and 2,356 during the approval phase of Claritin's regulatory review.